- Over 70% of men in their 60’s have an enlarged prostate1
- This year in Australia alone over 1 million men will suffer from lower urinary symptoms2.
- Benign Prostatic Hyperplasia (BPH), or enlarged prostate affects more than 500 million men worldwide1.
NeoTract, Australia Pty. Ltd, today announced publication of the five-year results of the company’s pivotal, randomized L.I.F.T. study in the Canadian Journal of Urology.
This study evaluated the safety and effectiveness of the company’s unique UroLift® System as a treatment for patients with symptomatic benign prostatic hyperplasia (BPH), or enlarged prostate.
In the publication, the authors conclude that the five-year results from the study demonstrate that the UroLift System has reached maturity as a standard of care for BPH.
The procedure rapidly and durably reduces symptoms and improves quality of life for men with benign prostatic hyperplasia, without compromising sexual function.
“These results demonstrate both the clinical advantages of the minimally invasive UroLift System as well as its definitive five-year durability,” says Associate Professor Chin of Wollongong Hospital, NSW, who has treated numerous patients as a part of the L.I.F.T. clinical trial. “From the surgeon’s perspective, the procedure is easily learned and quickly performed. It involves no cutting, heating, or removal of tissue, and results are evident immediately. I believe the UroLift System is a game-changer in the field of urology.”
“This is a proud moment for us in Australia as the history of the UroLift System saw the original clinical research being carried out here from 2005, initially by two Urologists in NSW and then soon expanding across five Australian sites,“ says David Baker General Manager of NeoTract Australia.
About the UroLift® System
The UroLift permanent retractors are delivered during a minimally invasive transurethral outpatient procedure, to relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Most procedural symptoms were mild to moderate in severity and resolved within two to four weeks after the treatment. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. The UroLift System has been available for use in Australia with reimbursement for men holding private health insurance since February 2013. Learn more at www.UroLift.com.au
NeoTract Australia Pty. Ltd
NeoTract Australia Pty. Ltd. is a wholly owned subsidiary of NeoTract, Inc., based in Pleasanton, California. dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH or enlarged Prostate using the UroLift System, a minimally invasive permanent implant system that treats lower Urinary Tract symptoms while preserving normal sexual function. Learn more at www.UroLift.com.au